SCHEMBL157184

SCHEMBL157184

[c]1nncc2c1CCCCCC2

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12520764 0.98 SIGMAR1 (0.32) SIGMAR1
SCHEMBL17239956 0.69 PNMT (0.36)
SCHEMBL5021296 0.67 SIGMAR1 (0.50) SIGMAR1
SCHEMBL17240236 0.65 NNMT (0.32)
SCHEMBL154827 0.65 SIGMAR1 (0.40) SIGMAR1
SCHEMBL17239990 0.65
SCHEMBL15067 0.62 SIGMAR1 (0.41) SIGMAR1
SCHEMBL5048733 0.62 SIGMAR1 (0.46) SIGMAR1
SCHEMBL20554291 0.62
SCHEMBL5021300 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2035 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170050970-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. 2017-02-23 US claimed
WO-2024151489-A1 PHARMACEUTICAL PYRIDYL COMPOSITIONS AND METHODS FOR USE Unicycive Therapeutics Inc. (US) 2024-07-18 WO disclosed
US-20240238458-A1 COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF PURDUE RESEARCH FOUNDATION 2024-07-18 US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 US disclosed
US-12036211-B2 Nicorandil derivatives Unicycive Therapeutics Inc. (US) 2024-07-16 US disclosed
US-12036078-B2 Oral products and methods for producing the same PolySpectra, Inc. (US) 2024-07-16 US disclosed
WO-2024148191-A1 MODULATORS OF TNF-α ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2024-07-11 WO disclosed
US-12029708-B2 Alkoxy compounds for disease treatment ACUCELA INC. (US) 2024-07-09 US disclosed
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-07-09 US disclosed
CN-118290403-A Benzamide derivatives of pyrazolyl-amino-pyrimidinyl and compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-05 CN disclosed
WO-2009018338-A2 PHOSPHORYLATED PYRONE ANALOGS AND METHODS LIMERICK BIOPHARMA, INC. (US) 2009-02-05 WO disclosed
WO-2009018326-A2 SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS LIMERICK BIOPHARMA, INC. (US) 2009-02-05 WO disclosed
WO-2009005794-A2 ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2009-01-08 WO disclosed
US-20080316678-A1 Nanoparticle ultracapacitor DAIS ANALYTIC CORPORATION 2008-12-25 US disclosed
WO-2008141179-A1 MOLECULE SULFONATION PROCESS AEGIS BIOSCIENCES LLP (US) 2008-11-20 WO disclosed
WO-2008131368-A2 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. (US) 2008-10-30 WO disclosed
US-20080227789-A1 DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2008-09-18 US disclosed
WO-2008089484-A1 MULTI-PHASE SELECTIVE MASS TRANSFER THROUGH A MEMBRANE DAIS ANALYTIC CORPORATION (US) 2008-07-24 WO disclosed
WO-2008080134-A2 4-AMIN0-2- (HETERO) ARYLAMINO-5- (HETERO) ARYLTHIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed
WO-2008039779-A2 ENHANCED HVAC SYSTEM AND METHOD DAIS ANALYTIC CORPORATION (US) 2008-04-03 WO disclosed